| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, X-Ray Computed | 47 | 2021 | 7551 | 3.890 |
Why?
|
| Mediastinal Neoplasms | 11 | 2021 | 423 | 3.660 |
Why?
|
| Mediastinum | 12 | 2021 | 268 | 3.420 |
Why?
|
| Lung Neoplasms | 55 | 2023 | 11538 | 3.050 |
Why?
|
| Diagnostic Imaging | 21 | 2021 | 1162 | 3.000 |
Why?
|
| Thoracic Neoplasms | 9 | 2019 | 337 | 2.330 |
Why?
|
| Magnetic Resonance Imaging | 19 | 2021 | 7702 | 2.270 |
Why?
|
| Thoracic Wall | 8 | 2021 | 183 | 1.970 |
Why?
|
| Multimodal Imaging | 10 | 2018 | 550 | 1.930 |
Why?
|
| Thymus Neoplasms | 8 | 2021 | 400 | 1.860 |
Why?
|
| Positron Emission Tomography Computed Tomography | 17 | 2022 | 833 | 1.720 |
Why?
|
| Multidetector Computed Tomography | 5 | 2018 | 150 | 1.610 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 20 | 2023 | 5319 | 1.550 |
Why?
|
| Radiography, Thoracic | 9 | 2019 | 462 | 1.520 |
Why?
|
| Positron-Emission Tomography | 14 | 2020 | 2173 | 1.510 |
Why?
|
| Immunotherapy | 9 | 2021 | 3341 | 1.470 |
Why?
|
| Fluorodeoxyglucose F18 | 15 | 2022 | 1226 | 1.360 |
Why?
|
| Thoracic Diseases | 3 | 2018 | 31 | 1.290 |
Why?
|
| Lung | 24 | 2021 | 3151 | 1.290 |
Why?
|
| Pleural Neoplasms | 6 | 2022 | 470 | 1.240 |
Why?
|
| Radiopharmaceuticals | 13 | 2020 | 1301 | 1.210 |
Why?
|
| Neoplasms, Glandular and Epithelial | 4 | 2021 | 519 | 1.160 |
Why?
|
| Mass Screening | 5 | 2017 | 1509 | 1.040 |
Why?
|
| Mediastinal Diseases | 2 | 2021 | 56 | 0.910 |
Why?
|
| Humans | 138 | 2023 | 261506 | 0.850 |
Why?
|
| Vascular Diseases | 2 | 2015 | 246 | 0.840 |
Why?
|
| Early Detection of Cancer | 5 | 2017 | 1258 | 0.810 |
Why?
|
| Mesothelioma | 5 | 2022 | 544 | 0.790 |
Why?
|
| Thorax | 6 | 2020 | 213 | 0.760 |
Why?
|
| Lymphatic Metastasis | 10 | 2021 | 4844 | 0.730 |
Why?
|
| Societies, Medical | 10 | 2021 | 1335 | 0.730 |
Why?
|
| Pulmonary Artery | 2 | 2014 | 499 | 0.730 |
Why?
|
| Lymph Nodes | 7 | 2021 | 2967 | 0.710 |
Why?
|
| Heart Neoplasms | 2 | 2020 | 214 | 0.700 |
Why?
|
| Incidental Findings | 5 | 2021 | 272 | 0.700 |
Why?
|
| Esophageal Neoplasms | 10 | 2021 | 3168 | 0.690 |
Why?
|
| Neoplasm Staging | 17 | 2022 | 13658 | 0.660 |
Why?
|
| Radiology | 4 | 2019 | 434 | 0.640 |
Why?
|
| Blast Injuries | 1 | 2018 | 48 | 0.620 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 160 | 0.620 |
Why?
|
| Thoracic Injuries | 1 | 2018 | 58 | 0.620 |
Why?
|
| Solitary Pulmonary Nodule | 2 | 2016 | 123 | 0.620 |
Why?
|
| Multiple Trauma | 1 | 2018 | 64 | 0.610 |
Why?
|
| Wounds, Penetrating | 1 | 2018 | 89 | 0.610 |
Why?
|
| Diagnosis, Differential | 15 | 2019 | 4744 | 0.600 |
Why?
|
| Pulmonary Embolism | 2 | 2019 | 329 | 0.590 |
Why?
|
| Journalism, Medical | 1 | 2016 | 11 | 0.580 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2017 | 59 | 0.570 |
Why?
|
| Radiologists | 2 | 2021 | 163 | 0.570 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2018 | 176 | 0.560 |
Why?
|
| Radiology Information Systems | 1 | 2017 | 114 | 0.550 |
Why?
|
| Contrast Media | 9 | 2019 | 1472 | 0.540 |
Why?
|
| Aortic Diseases | 1 | 2018 | 206 | 0.530 |
Why?
|
| Diagnostic Errors | 5 | 2018 | 509 | 0.520 |
Why?
|
| Documentation | 1 | 2017 | 207 | 0.520 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 403 | 0.510 |
Why?
|
| Unnecessary Procedures | 2 | 2019 | 104 | 0.510 |
Why?
|
| Adenosine Triphosphate | 1 | 2017 | 571 | 0.510 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 402 | 0.500 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2018 | 1249 | 0.450 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 1021 | 0.450 |
Why?
|
| Aorta, Thoracic | 1 | 2018 | 546 | 0.450 |
Why?
|
| False Positive Reactions | 5 | 2017 | 355 | 0.440 |
Why?
|
| Fellowships and Scholarships | 1 | 2016 | 390 | 0.430 |
Why?
|
| Cancer Care Facilities | 1 | 2017 | 884 | 0.420 |
Why?
|
| Periodicals as Topic | 1 | 2016 | 338 | 0.420 |
Why?
|
| Thymoma | 1 | 2015 | 246 | 0.400 |
Why?
|
| Referral and Consultation | 1 | 2017 | 899 | 0.390 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 592 | 0.390 |
Why?
|
| Neoplasms | 10 | 2021 | 15193 | 0.380 |
Why?
|
| Lung Diseases | 3 | 2021 | 717 | 0.360 |
Why?
|
| Quality Improvement | 1 | 2017 | 851 | 0.360 |
Why?
|
| Ipilimumab | 4 | 2023 | 710 | 0.360 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2014 | 406 | 0.350 |
Why?
|
| Radiography | 4 | 2019 | 1904 | 0.350 |
Why?
|
| Exons | 3 | 2022 | 1328 | 0.320 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2015 | 882 | 0.310 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2330 | 0.310 |
Why?
|
| United States | 15 | 2023 | 15433 | 0.290 |
Why?
|
| Biopsy | 1 | 2014 | 3443 | 0.280 |
Why?
|
| Male | 35 | 2022 | 123000 | 0.270 |
Why?
|
| Evidence-Based Medicine | 9 | 2021 | 1085 | 0.270 |
Why?
|
| Hydrazines | 3 | 2022 | 208 | 0.260 |
Why?
|
| Lymphoma | 1 | 2014 | 1467 | 0.260 |
Why?
|
| Radiotherapy | 3 | 2019 | 1824 | 0.260 |
Why?
|
| Retrospective Studies | 19 | 2023 | 37905 | 0.250 |
Why?
|
| Heart | 4 | 2020 | 1223 | 0.250 |
Why?
|
| Adenocarcinoma | 4 | 2017 | 7789 | 0.250 |
Why?
|
| Middle Aged | 25 | 2021 | 86204 | 0.240 |
Why?
|
| Radiation Dosage | 3 | 2019 | 1014 | 0.230 |
Why?
|
| B7-H1 Antigen | 5 | 2023 | 1022 | 0.230 |
Why?
|
| Radiosurgery | 3 | 2023 | 1330 | 0.230 |
Why?
|
| Aged | 23 | 2022 | 70117 | 0.230 |
Why?
|
| Neoplasms, Second Primary | 2 | 2022 | 1350 | 0.230 |
Why?
|
| Precancerous Conditions | 2 | 2021 | 1058 | 0.230 |
Why?
|
| Melanoma | 4 | 2023 | 5317 | 0.220 |
Why?
|
| Female | 32 | 2022 | 141928 | 0.220 |
Why?
|
| Heart Defects, Congenital | 1 | 2014 | 1697 | 0.210 |
Why?
|
| Smoking | 3 | 2017 | 2440 | 0.210 |
Why?
|
| Quinazolines | 3 | 2022 | 923 | 0.210 |
Why?
|
| Adult | 17 | 2021 | 77950 | 0.210 |
Why?
|
| Genes, erbB | 1 | 2021 | 26 | 0.200 |
Why?
|
| Radiographic Image Enhancement | 3 | 2019 | 402 | 0.190 |
Why?
|
| Neoadjuvant Therapy | 5 | 2023 | 4975 | 0.190 |
Why?
|
| Thymus Gland | 3 | 2021 | 294 | 0.190 |
Why?
|
| Public Opinion | 1 | 2021 | 83 | 0.190 |
Why?
|
| Receptor, ErbB-2 | 2 | 2021 | 2518 | 0.180 |
Why?
|
| Karyopherins | 1 | 2021 | 136 | 0.180 |
Why?
|
| Triazoles | 2 | 2021 | 617 | 0.180 |
Why?
|
| Thoracic Outlet Syndrome | 1 | 2020 | 25 | 0.180 |
Why?
|
| Radiation Injuries | 2 | 2019 | 1411 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2023 | 15862 | 0.180 |
Why?
|
| Lymphatic Vessels | 1 | 2020 | 143 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2022 | 5178 | 0.180 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 4892 | 0.170 |
Why?
|
| Abdominal Cavity | 1 | 2019 | 20 | 0.170 |
Why?
|
| Chemoradiotherapy | 2 | 2018 | 1946 | 0.170 |
Why?
|
| ErbB Receptors | 4 | 2022 | 2295 | 0.170 |
Why?
|
| Uveal Neoplasms | 1 | 2020 | 176 | 0.170 |
Why?
|
| Flail Chest | 1 | 2018 | 4 | 0.160 |
Why?
|
| Pneumopericardium | 1 | 2018 | 4 | 0.160 |
Why?
|
| Circulating Tumor DNA | 1 | 2021 | 235 | 0.160 |
Why?
|
| Benchmarking | 1 | 2020 | 273 | 0.160 |
Why?
|
| Hemothorax | 1 | 2018 | 20 | 0.160 |
Why?
|
| Urogenital Neoplasms | 1 | 2019 | 108 | 0.160 |
Why?
|
| Leukemia, Lymphoid | 1 | 2019 | 276 | 0.160 |
Why?
|
| Respiratory Tract Diseases | 1 | 2018 | 111 | 0.160 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2018 | 141 | 0.160 |
Why?
|
| Rib Fractures | 1 | 2018 | 30 | 0.160 |
Why?
|
| Clinical Trials as Topic | 3 | 2019 | 3719 | 0.160 |
Why?
|
| Artifacts | 3 | 2018 | 532 | 0.160 |
Why?
|
| Digestive System Diseases | 1 | 2018 | 35 | 0.160 |
Why?
|
| Tumor Microenvironment | 4 | 2021 | 2864 | 0.150 |
Why?
|
| Computed Tomography Angiography | 1 | 2019 | 234 | 0.150 |
Why?
|
| Acute Disease | 3 | 2019 | 2422 | 0.150 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2018 | 133 | 0.150 |
Why?
|
| Thyroid Nodule | 1 | 2018 | 92 | 0.150 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2018 | 216 | 0.150 |
Why?
|
| Lymphadenopathy | 1 | 2018 | 90 | 0.150 |
Why?
|
| Bronchial Neoplasms | 1 | 2017 | 79 | 0.150 |
Why?
|
| Sensitivity and Specificity | 7 | 2019 | 4971 | 0.150 |
Why?
|
| Pulmonary Eosinophilia | 1 | 2016 | 13 | 0.140 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2021 | 591 | 0.140 |
Why?
|
| Machine Learning | 1 | 2019 | 319 | 0.140 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2018 | 170 | 0.140 |
Why?
|
| Pneumothorax | 1 | 2018 | 153 | 0.140 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2016 | 26 | 0.140 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2016 | 34 | 0.140 |
Why?
|
| Journal Impact Factor | 1 | 2016 | 40 | 0.140 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2019 | 388 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2022 | 4757 | 0.140 |
Why?
|
| Mutation | 6 | 2022 | 15179 | 0.140 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2016 | 72 | 0.140 |
Why?
|
| Bronchial Diseases | 1 | 2015 | 45 | 0.130 |
Why?
|
| Tracheal Diseases | 1 | 2015 | 32 | 0.130 |
Why?
|
| Fiducial Markers | 1 | 2016 | 96 | 0.130 |
Why?
|
| Quality Control | 1 | 2017 | 457 | 0.130 |
Why?
|
| Nomograms | 1 | 2018 | 313 | 0.130 |
Why?
|
| Dyspnea | 1 | 2018 | 416 | 0.130 |
Why?
|
| Observer Variation | 1 | 2017 | 671 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2019 | 437 | 0.130 |
Why?
|
| Pulmonary Alveoli | 1 | 2016 | 208 | 0.130 |
Why?
|
| Terminology as Topic | 1 | 2017 | 414 | 0.130 |
Why?
|
| Consensus | 2 | 2021 | 978 | 0.130 |
Why?
|
| Myocardium | 2 | 2020 | 1313 | 0.130 |
Why?
|
| Immunocompromised Host | 1 | 2019 | 698 | 0.130 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2017 | 199 | 0.130 |
Why?
|
| Evolution, Molecular | 1 | 2019 | 834 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 992 | 0.130 |
Why?
|
| Pleura | 3 | 2022 | 127 | 0.130 |
Why?
|
| Cardiovascular Diseases | 2 | 2018 | 2195 | 0.120 |
Why?
|
| Esophagus | 4 | 2021 | 553 | 0.120 |
Why?
|
| Dasatinib | 1 | 2017 | 862 | 0.120 |
Why?
|
| Lung Diseases, Fungal | 1 | 2015 | 124 | 0.120 |
Why?
|
| Publishing | 1 | 2016 | 220 | 0.120 |
Why?
|
| Body Weight | 1 | 2019 | 1293 | 0.120 |
Why?
|
| Leukemia, Myeloid | 1 | 2019 | 941 | 0.120 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2016 | 304 | 0.110 |
Why?
|
| Postoperative Care | 1 | 2017 | 739 | 0.110 |
Why?
|
| Membrane Glycoproteins | 1 | 2018 | 1073 | 0.110 |
Why?
|
| Induction Chemotherapy | 1 | 2016 | 669 | 0.110 |
Why?
|
| Genital Neoplasms, Female | 1 | 2019 | 735 | 0.110 |
Why?
|
| Prognosis | 7 | 2021 | 21713 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 2403 | 0.110 |
Why?
|
| Reproducibility of Results | 6 | 2019 | 6009 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 3251 | 0.100 |
Why?
|
| Breast | 1 | 2019 | 1344 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 1148 | 0.100 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 1331 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2022 | 10035 | 0.100 |
Why?
|
| Treatment Outcome | 7 | 2022 | 32848 | 0.100 |
Why?
|
| Antineoplastic Agents | 4 | 2018 | 14289 | 0.100 |
Why?
|
| DNA Methylation | 1 | 2021 | 2669 | 0.090 |
Why?
|
| Disease Progression | 2 | 2021 | 6682 | 0.090 |
Why?
|
| Algorithms | 2 | 2019 | 3890 | 0.090 |
Why?
|
| Ovarian Neoplasms | 2 | 2022 | 4638 | 0.090 |
Why?
|
| Survival Rate | 5 | 2021 | 12221 | 0.080 |
Why?
|
| Pneumonia | 1 | 2015 | 751 | 0.080 |
Why?
|
| Hyperplasia | 2 | 2021 | 557 | 0.080 |
Why?
|
| Neoplasm Metastasis | 4 | 2019 | 5112 | 0.080 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2018 | 2370 | 0.080 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 10331 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2023 | 4849 | 0.070 |
Why?
|
| Glycolysis | 2 | 2020 | 519 | 0.070 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 29902 | 0.070 |
Why?
|
| Proton Therapy | 1 | 2016 | 1577 | 0.070 |
Why?
|
| Combined Modality Therapy | 3 | 2023 | 8865 | 0.070 |
Why?
|
| Paclitaxel | 2 | 2022 | 1996 | 0.060 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2018 | 565 | 0.060 |
Why?
|
| Risk Factors | 3 | 2019 | 17523 | 0.060 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 14889 | 0.060 |
Why?
|
| Carcinogenesis | 2 | 2021 | 1026 | 0.060 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 2576 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2017 | 5542 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 4938 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2018 | 1048 | 0.050 |
Why?
|
| Pericardium | 1 | 2022 | 157 | 0.050 |
Why?
|
| Thoracic Duct | 1 | 2020 | 16 | 0.050 |
Why?
|
| Lymph | 1 | 2020 | 76 | 0.050 |
Why?
|
| Genes, Suppressor | 1 | 2000 | 25 | 0.050 |
Why?
|
| Aspergillus nidulans | 1 | 2000 | 28 | 0.050 |
Why?
|
| Genes, Fungal | 1 | 2000 | 84 | 0.050 |
Why?
|
| Chest Pain | 1 | 2021 | 155 | 0.050 |
Why?
|
| Topotecan | 1 | 2021 | 239 | 0.050 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2021 | 323 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2020 | 12873 | 0.050 |
Why?
|
| Mutation Rate | 1 | 2021 | 223 | 0.050 |
Why?
|
| Chromosomal Instability | 1 | 2021 | 233 | 0.040 |
Why?
|
| Vomiting | 1 | 2021 | 354 | 0.040 |
Why?
|
| Fungal Proteins | 1 | 2000 | 254 | 0.040 |
Why?
|
| Diaphragm | 1 | 2020 | 181 | 0.040 |
Why?
|
| Nausea | 1 | 2021 | 525 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2019 | 68 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2021 | 483 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2021 | 318 | 0.040 |
Why?
|
| Workflow | 1 | 2020 | 275 | 0.040 |
Why?
|
| Cyclins | 1 | 2000 | 456 | 0.040 |
Why?
|
| Tertiary Healthcare | 1 | 2019 | 44 | 0.040 |
Why?
|
| Receptors, Purinergic P1 | 1 | 2018 | 25 | 0.040 |
Why?
|
| Carboplatin | 1 | 2021 | 823 | 0.040 |
Why?
|
| Ventricular Septum | 1 | 2018 | 19 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2021 | 1163 | 0.040 |
Why?
|
| China | 1 | 2019 | 606 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 649 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2019 | 726 | 0.040 |
Why?
|
| Arginine Vasopressin | 1 | 2018 | 60 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2021 | 1290 | 0.040 |
Why?
|
| Mutagenesis, Insertional | 1 | 2018 | 218 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2023 | 2315 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 344 | 0.040 |
Why?
|
| Image-Guided Biopsy | 1 | 2019 | 327 | 0.040 |
Why?
|
| Capecitabine | 1 | 2018 | 388 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 6550 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2019 | 665 | 0.040 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 388 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2019 | 604 | 0.040 |
Why?
|
| Cysts | 1 | 2017 | 197 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 846 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2019 | 6869 | 0.030 |
Why?
|
| Tretinoin | 1 | 2018 | 623 | 0.030 |
Why?
|
| Thyroid Gland | 1 | 2018 | 355 | 0.030 |
Why?
|
| Metals | 1 | 2016 | 155 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 341 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2019 | 619 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2018 | 10001 | 0.030 |
Why?
|
| Taxes | 1 | 2014 | 7 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 7222 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2018 | 1313 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2018 | 324 | 0.030 |
Why?
|
| History, 16th Century | 1 | 2014 | 34 | 0.030 |
Why?
|
| History, 17th Century | 1 | 2014 | 40 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2019 | 636 | 0.030 |
Why?
|
| History, 18th Century | 1 | 2014 | 89 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2021 | 1863 | 0.030 |
Why?
|
| History, 19th Century | 1 | 2014 | 154 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2018 | 938 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2018 | 1144 | 0.030 |
Why?
|
| Muscle, Striated | 1 | 2013 | 14 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2016 | 295 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 1516 | 0.030 |
Why?
|
| Peritoneal Neoplasms | 1 | 2020 | 821 | 0.030 |
Why?
|
| Smoking Prevention | 1 | 2014 | 138 | 0.030 |
Why?
|
| Blood Vessels | 1 | 2015 | 217 | 0.030 |
Why?
|
| Binding Sites | 1 | 2018 | 2171 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2018 | 1944 | 0.030 |
Why?
|
| Iopamidol | 1 | 2013 | 9 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 1742 | 0.030 |
Why?
|
| Esophagectomy | 1 | 2018 | 911 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2018 | 1819 | 0.030 |
Why?
|
| Adipose Tissue, Brown | 1 | 2013 | 112 | 0.030 |
Why?
|
| Mice | 3 | 2018 | 34495 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2014 | 441 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 2139 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 973 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 2291 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 1987 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2014 | 574 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2018 | 2450 | 0.030 |
Why?
|
| Patient Selection | 1 | 2019 | 2055 | 0.030 |
Why?
|
| Transcriptome | 1 | 2020 | 1859 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 2594 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1945 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 1586 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 980 | 0.020 |
Why?
|
| Young Adult | 2 | 2019 | 21445 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2016 | 1271 | 0.020 |
Why?
|
| Genomics | 1 | 2021 | 2738 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2013 | 417 | 0.020 |
Why?
|
| Cell Line | 1 | 2018 | 5114 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2018 | 3842 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2016 | 1529 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 1323 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 3821 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2021 | 9180 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 4320 | 0.020 |
Why?
|
| Animals | 3 | 2018 | 59536 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2014 | 712 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 2307 | 0.020 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2018 | 2104 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 3260 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 9244 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2018 | 8223 | 0.020 |
Why?
|
| Texas | 1 | 2016 | 6311 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 4557 | 0.010 |
Why?
|
| Infant | 1 | 2018 | 13310 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 14551 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 8873 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2018 | 16273 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2018 | 11965 | 0.010 |
Why?
|
| Child | 1 | 2018 | 29154 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 31252 | 0.010 |
Why?
|